Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Advances in CD22/CD19 CAR-T sequential therapy

Jianxiang Wang • 6 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia CAR-T

In this video, Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, talks on CAR-T therapy for the treatment of acute lymphoblastic leukemia (ALL). Dr Wang discusses the need to reduce the risk of relapse following CD19 CAR-T therapy and describes ongoing trials investigating CD22/CD19 CAR-T sequential therapy, which demonstrate high efficacy and a prolonged duration of remission. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Advisor of AbbVie

More from Jianxiang Wang

COMMODORE: gilteritinib for the treatment of R/R FLT3-mutated AML
4:47
COMMODORE: gilteritinib for the treatment of R/R FLT3-mutated AML
Jianxiang Wang • 6 Jun 2022
The clinical characteristics and prognosis of adults with Ph-ALL with TP53 aberrations
3:13
The clinical characteristics and prognosis of adults with Ph-ALL with TP53 aberrations
Jianxiang Wang • 6 Jun 2022
Progression of CAR-T trials in China
2:12
Progression of CAR-T trials in China
Jianxiang Wang • 2 Feb 2021
CAR-T trials to watch in China
3:14
CAR-T trials to watch in China
Jianxiang Wang • 2 Feb 2021

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals